Cellectar Biosciences Stock Fundamentals
| CLRB Stock | USD 0.32 0.02 6.67% |
Cellectar Biosciences fundamentals help investors to digest information that contributes to Cellectar Biosciences' financial success or failures. It also enables traders to predict the movement of Cellectar Stock. The fundamental analysis module provides a way to measure Cellectar Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cellectar Biosciences stock.
At present, Cellectar Biosciences' Depreciation And Amortization is projected to decrease significantly based on the last few years of reporting. The current year's Interest Expense is expected to grow to about 363.4 K, whereas Gross Profit is forecasted to decline to (181.8 K).
Cellectar | Select Account or Indicator |
Cellectar Biosciences Company Shares Outstanding Analysis
Cellectar Biosciences' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Cellectar Biosciences Shares Outstanding | 46.08 M |
Most of Cellectar Biosciences' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cellectar Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cellectar Shares Outstanding Historical Pattern
Today, most investors in Cellectar Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cellectar Biosciences' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Cellectar Biosciences shares outstanding as a starting point in their analysis.
Cellectar Biosciences Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Cellectar Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
At present, Cellectar Biosciences' Common Stock Shares Outstanding is projected to increase significantly based on the last few years of reporting.
Based on the latest financial disclosure, Cellectar Biosciences has 46.08 M of shares currently outstending. This is 74.48% lower than that of the Biotechnology sector and 56.88% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 91.94% higher than that of the company.
Cellectar Biosciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cellectar Biosciences's current stock value. Our valuation model uses many indicators to compare Cellectar Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cellectar Biosciences competition to find correlations between indicators driving Cellectar Biosciences's intrinsic value. More Info.Cellectar Biosciences is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At present, Cellectar Biosciences' Return On Equity is projected to increase slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cellectar Biosciences' earnings, one of the primary drivers of an investment's value.Cellectar Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cellectar Biosciences' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cellectar Biosciences could also be used in its relative valuation, which is a method of valuing Cellectar Biosciences by comparing valuation metrics of similar companies.Cellectar Biosciences is currently under evaluation in shares outstanding category among its peers.
Cellectar Fundamentals
| Return On Equity | -4.75 | ||||
| Return On Asset | -1.1 | ||||
| Current Valuation | (5.55 M) | ||||
| Shares Outstanding | 46.08 M | ||||
| Shares Owned By Insiders | 1.64 % | ||||
| Shares Owned By Institutions | 10.99 % | ||||
| Number Of Shares Shorted | 2.34 M | ||||
| Price To Earning | (1.35) X | ||||
| Price To Book | 9.42 X | ||||
| EBITDA | (51.78 M) | ||||
| Net Income | (44.58 M) | ||||
| Cash And Equivalents | 24.81 M | ||||
| Cash Per Share | 4.06 X | ||||
| Total Debt | 494 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 4.51 X | ||||
| Book Value Per Share | 0.04 X | ||||
| Cash Flow From Operations | (32.38 M) | ||||
| Short Ratio | 1.72 X | ||||
| Earnings Per Share | (1.41) X | ||||
| Target Price | 8.0 | ||||
| Beta | 0.97 | ||||
| Market Capitalization | 13.81 M | ||||
| Total Asset | 25.47 M | ||||
| Retained Earnings | (247.34 M) | ||||
| Working Capital | (2.48 M) | ||||
| Current Asset | 8.14 M | ||||
| Current Liabilities | 1.39 M | ||||
| Net Asset | 25.47 M |
About Cellectar Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cellectar Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cellectar Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cellectar Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 2.8 M | 2.9 M | |
| Cost Of Revenue | 221.2 K | 282.5 K | |
| Stock Based Compensation To Revenue | (94.87) | (90.13) | |
| Sales General And Administrative To Revenue | 67.12 | 70.48 | |
| Research And Ddevelopement To Revenue | (376.27) | (357.45) | |
| Capex To Revenue | (12.38) | (11.76) | |
| Revenue Per Share | (10.57) | (10.04) | |
| Ebit Per Revenue | 575.81 | 604.60 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cellectar Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cellectar Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cellectar Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cellectar Biosciences Stock:Check out Cellectar Biosciences Piotroski F Score and Cellectar Biosciences Altman Z Score analysis. For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cellectar Biosciences. If investors know Cellectar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cellectar Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cellectar Biosciences is measured differently than its book value, which is the value of Cellectar that is recorded on the company's balance sheet. Investors also form their own opinion of Cellectar Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cellectar Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cellectar Biosciences' market value can be influenced by many factors that don't directly affect Cellectar Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cellectar Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cellectar Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cellectar Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.